---
id: 242
title: Pseudomonas aeruginosa
category: organisms
subcategory: gram_negative_rods
tags: [Pseudomonas, cystic-fibrosis, IVDU, hot-tub, ecthyma-gangrenosum, antipseudomonal]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Pseudomonas aeruginosa*? Use **"Double Cover if Severe (β-Lactam + Aminoglycoside/Fluoroquinolone), CF/Bronchiectasis, IVDU, Immunocompromised"** framework.

## Answer

### **Key Clinical Syndromes:**

**Pneumonia:**
- **Ventilator-associated pneumonia (VAP)** - common
- **Cystic fibrosis, bronchiectasis** - chronic colonization/infection
- **Immunocompromised** (neutropenia) - high mortality

**Bacteremia/Sepsis:**
- **Ecthyma gangrenosum** (pathognomonic skin lesion - necrotic ulcer with erythematous halo)
- **Often neutropenic patients**
- **High mortality** (30-60%)

**Urinary Tract Infections:**
- **Catheter-associated**
- **Structural abnormalities**

**Skin/Soft Tissue:**
- **Burn wound infections**
- **Hot tub folliculitis** (self-limited)
- **Nail infections** (green nail syndrome)
- **Diabetic foot ulcers** (polymicrobial)

**Bone/Joint:**
- **Osteomyelitis** (diabetic foot, vertebral in IVDU)
- **Sternoclavicular/SI joint** (IVDU)

**Ear:**
- **Otitis externa** ("swimmer's ear")
- **Malignant otitis externa** (diabetics, elderly) - invasive, skull base osteomyelitis

**Eye:**
- **Keratitis** (contact lenses)
- **Endophthalmitis** (post-surgical, trauma)

**CNS:**
- **Meningitis** (post-neurosurgery, trauma)
- **Brain abscess** (IVDU, hematogenous)

### **Antimicrobial Resistance:**

**Intrinsic Resistance:**
- **AmpC beta-lactamase** (inducible)
- **Efflux pumps** (reduces intracellular antibiotic concentration)
- **Low outer membrane permeability**

**Acquired Resistance:**
- **ESBL, carbapenemases** (KPC, VIM, NDM)
- **Multidrug-resistant (MDR):** Resistant to ≥3 classes
- **Extensively drug-resistant (XDR):** Resistant to all but ≤2 classes
- **Pan-drug-resistant (PDR):** Resistant to all classes

**Risk Factors for MDR:**
- **Recent antibiotics** (especially carbapenems, fluoroquinolones)
- **ICU stay, mechanical ventilation**
- **Cystic fibrosis** (chronic suppressive therapy)
- **Healthcare exposure**

### **Treatment:**

**General Principles:**
- **Double coverage** (β-lactam + aminoglycoside OR fluoroquinolone) if:
  - **Severe infection** (septic shock, neutropenic fever, pneumonia)
  - **High risk for MDR**
  - **Can narrow to monotherapy** once susceptibilities available

**Antipseudomonal Agents:**

**β-Lactams:**
- **Pip-tazo 4.5g IV q6h** (extended infusion preferred)
- **Cefepime 2g IV q8h** (extended infusion)
- **Ceftazidime 2g IV q8h**
- **Meropenem 1-2g IV q8h** OR **imipenem 500mg-1g IV q6-8h**
- **Aztreonam 2g IV q8h** (if β-lactam allergy)

**Aminoglycosides:**
- **Tobramycin 7 mg/kg IV daily** (once-daily dosing)
- **Amikacin 20 mg/kg IV daily**
- **Use for double coverage**, usually short-term (3-7 days)

**Fluoroquinolones:**
- **Ciprofloxacin 400mg IV q8h** OR **750mg PO BID**
- **Levofloxacin 750mg IV/PO daily**
- **Resistance increasing** (20-40% in many centers)

**Polymyxins (Last Resort):**
- **Colistin (polymyxin E)** 5 mg/kg loading → 2.5 mg/kg IV q12h
- **Nephrotoxic, neurotoxic**
- **Use for MDR/XDR** when no alternatives

**Newer Agents (For MDR/XDR):**
- **Ceftolozane-tazobactam 1.5g IV q8h** (excellent anti-*Pseudomonas* activity)
- **Ceftazidime-avibactam 2.5g IV q8h** (active against some carbapenem-resistant strains)
- **Imipenem-cilastatin-relebactam 1.25g IV q6h**

### **Treatment by Syndrome:**

**Pneumonia (Non-CF):**
- **Pip-tazo 4.5g IV q6h** OR **cefepime 2g IV q8h** OR **meropenem 1g IV q8h**
- **+ Aminoglycoside** (tobramycin, amikacin) × 3-7 days OR **ciprofloxacin**
- **Duration:** 7-14 days

**Bacteremia/Sepsis:**
- **Double coverage** (β-lactam + aminoglycoside OR fluoroquinolone)
- **Duration:** 14 days (longer if metastatic foci)

**Cystic Fibrosis Exacerbation:**
- **Inhaled tobramycin 300mg BID** (chronic suppression)
- **Exacerbation:** IV β-lactam + aminoglycoside × 14-21 days

**UTI:**
- **Ciprofloxacin 500mg PO BID × 7 days** (if susceptible)
- **Cefepime, meropenem** (if resistant)

**Osteomyelitis:**
- **Prolonged therapy** (4-6 weeks)
- **Ciprofloxacin 750mg PO BID** (high oral bioavailability)

**Malignant Otitis Externa:**
- **Ciprofloxacin 750mg PO BID** OR **400mg IV q8h × 4-6 weeks**
- **+ Debridement** if needed

**MDR/XDR *Pseudomonas*:**
- **Ceftolozane-tazobactam, ceftazidime-avibactam**
- **Combination therapy** (e.g., β-lactam + aminoglycoside + colistin)
- **Consult ID specialist**

### **Virulence Factors:**

- **Exotoxin A** (inhibits protein synthesis, similar mechanism to diphtheria toxin)
- **Elastase** (tissue destruction)
- **Biofilm formation** (chronic infections, CF)
- **Alginate** (mucoid phenotype in CF, protects from immune clearance)

### **Special Considerations:**

**Cystic Fibrosis:**
- **Chronic colonization** (nearly all by adulthood)
- **Mucoid strains** (alginate production)
- **Chronic suppressive therapy** (inhaled tobramycin, azithromycin)

**IVDU:**
- **Vertebral osteomyelitis, epidural abscess**
- **Sternoclavicular/SI joint** septic arthritis

**Immunocompromised:**
- **High mortality** (bacteremia, pneumonia)
- **Ecthyma gangrenosum** (pathognomonic)

## Key Points

### **Double Cover if Severe:**
- **β-Lactam + aminoglycoside** OR **fluoroquinolone**
- **Septic shock, neutropenic fever, MDR risk**

### **Antipseudomonal β-Lactams:**
- **Pip-tazo, cefepime, ceftazidime, meropenem**

### **CF/Bronchiectasis:**
- **Chronic colonization**
- **Inhaled tobramycin** (suppression)

### **IVDU:**
- **Vertebral osteomyelitis, sternoclavicular joint**

### **Ecthyma Gangrenosum:**
- **Pathognomonic** for *Pseudomonas* bacteremia
- **Necrotic ulcer with erythematous halo**

### **Clinical Pearls:**
- **Double cover if severe:** β-lactam + aminoglycoside/fluoroquinolone
- **Antipseudomonal:** Pip-tazo, cefepime, meropenem, ciprofloxacin
- **CF:** Chronic colonization, inhaled tobramycin
- **IVDU:** Vertebral osteomyelitis, sternoclavicular/SI joint
- **Ecthyma gangrenosum:** Pathognomonic (necrotic ulcer + erythematous halo)
- **MDR/XDR:** Ceftolozane-tazobactam, ceftazidime-avibactam

## Sources

- [IDSA: *Pseudomonas aeruginosa* Infections 2024]
- [CID: MDR *Pseudomonas* Management 2024]

## Media

N/A
